Separate PDQ summaries on Lung Cancer Prevention, Small Cell Lung Cancer Treatment, Non-Small Cell Lung Cancer Treatment, and Levels of Evidence for Cancer Screening and Prevention Studies are also available.
There is evidence that screening persons aged 55 to 74 years who have cigarette smoking histories of 30 or more pack-years and who, if they are former smokers, have quit within the last 15 years reduces lung cancer mortality by 20% and all-cause mortality by 6.7%.
Magnitude of Effect: 20% relative reduction in lung cancer–specific mortality.
Based on solid evidence, screening would lead to false-positive tests in approximately one-quarter of those screened. Most abnormalities would be monitored radiographically. However, persons with false-positive screens and overdiagnosed cancers would be exposed to unnecessary invasive diagnostic procedures and treatments. Because of comorbidities among the heaviest smokers and those who have smoked for long periods of time, complications associated with invasive diagnostic procedures and therapy may be more frequent in these groups.
Magnitude of Effect: Positive. Magnitude is a 20% relative reduction in lung cancer–specific mortality and a 6.7% reduction in overall mortality.
Based on solid evidence, screening with chest x-ray and/or sputum cytology does not reduce mortality from lung cancer in the general population or in ever-smokers.
Magnitude of Effect: No evidence of effect.
Based on solid evidence, at least 95% of all positive chest x-ray screening exams (but not all) do not result in a lung cancer diagnosis. False-positive exams result in unnecessary invasive diagnostic procedures.
Based on solid evidence, some lung cancers detected by screening chest x-ray and/or sputum cytology appear to represent overdiagnosed cancer. Because of comorbidities, harms of diagnostic procedures and treatment may be most frequent among long-term and/or heavy smokers.
Magnitude of Effect: When calculated as the ratio of all lung cancer cases in the intervention arm to those in the control arm (percent excess cases), the magnitude of overdiagnosis ranges from 6%  to 17% .
Lung cancer is the third most common form of noncutaneous cancer in the United States and is the leading cause of cancer death in men and in women. In 2015 alone, it is estimated that there will be 221,200 new cases diagnosed, and 71,660 women and 86,380 men will die from this disease. The lung cancer death rate rose rapidly over several decades in both sexes, with a persistent decline for men commencing in 1991. From 2007 to 2011, death rates decreased by 2.9% per year in men and by 1.9% per year in women. 
The most important risk factor for lung cancer (as for many other cancers) is tobacco use.   Cigarette smoking has been definitively established by epidemiologic and preclinical animal experimental data as the primary cause of lung cancer. This causative link has been widely recognized since the 1960s, when national reports in Great Britain and the United States brought the cancer risk of smoking prominently to the public’s attention.  The percentages of lung cancers estimated to be caused by tobacco smoking in males and females are 90% and 78%, respectively.
Environmental or secondhand tobacco smoke is also implicated in causing lung cancer.  Environmental tobacco smoke has the same components as inhaled mainstream smoke, although in lower absolute concentrations; between 1% and 10%, depending on the constituent. Carcinogenic compounds in tobacco smoke include the polynuclear aromatic hydrocarbons (PAHs), including the classical carcinogen benzo[a]pyrene and the nicotine-derived tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). In rodents, total doses of both PAH and NNK that are similar to doses received by humans in a lifetime of smoking induce pulmonary tumors.  Elevated biomarkers of tobacco exposure, including urinary cotinine, tobacco-related carcinogen metabolites, and carcinogen-protein adducts, are seen in passive or secondhand smokers.     
Many other exposures have been established as causally associated with lung cancer, but even the combined effect of these additional factors is very small compared with cigarette smoking.  These additional causal factors are primarily related to occupational exposures to agents such as asbestos, arsenic, chromium, nickel, and radon.  Radon, a naturally occurring gas, is of relevance to the general public because of the potential exposure in homes. 
There have been intensive efforts to improve lung cancer screening with newer technologies, including low-dose helical computed tomography (LDCT) and molecular techniques.   LDCT was shown to be more sensitive than chest radiography. In the Early Lung Cancer Action Project (ELCAP),  LDCT detected almost six times as many stage I lung cancers as chest radiography, and most of these tumors were no larger than 1 cm in diameter. The ability of LDCT to reduce lung cancer mortality was demonstrated in the randomized, controlled National Lung Screening Trial (NLST): a statistically significant relative reduction of 20% in lung cancer mortality was observed, as was a statistically significant 6.7% relative reduction in all-cause mortality. 
Eight observational studies of LDCT in various parts of the world have been reported and summarized.  These are relatively small studies, ranging from about 600 to 8,000 participants, which began between 1992 and 2000. Most of the studies include a substantial percentage of females, and the studies in Japan include nonsmokers. Findings include a nodule or positivity rate of 5% to 51%, 0.4% to 3% lung cancers, 50% to 95% adenocarcinomas, 50% to 91% stage I or IA cancers, and estimates of sensitivity ranging from 40% to 95%.
False-positive test results and overdiagnosis must be considered when lung cancer screening with LDCT is being evaluated. The false-positive test result, which is more common than overdiagnosis, may lead to anxiety and invasive diagnostic procedures such as percutaneous needle biopsy or thoracotomy. In the ELCAP study,  which used a CT slice thickness of 10 mm, noncalcified nodules were detected in 21% of patients without lung cancer at the prevalence screen. Thirty-one (13%) of 233 individuals with noncalcified nodules underwent biopsies, of which close to 90% (27 of 31 patients) resulted in a diagnosis of malignancy, and the prevalence of cancers detected was 2.7%.
In a case series that defined the population at high risk of lung cancer by occupations associated with asbestos exposure, 58% accepted an invitation to participate in an LDCT screening program. The ELCAP screening protocol was applied in 1,119 asbestos-exposed people whose average age was 57 years. Twenty-five biopsies resulted in the detection of one stage IA and four late stage lung cancers. The authors concluded the screening program was not able to replicate the ELCAP results and was not cost effective for lung cancer screening in this population. 
A study in Ireland,  which aimed to reproduce the ELCAP study in high-risk but younger individuals, revealed a similar proportion of noncalcified nodules were detected using 10 mm CT slice thickness. In the Irish study (N = 449), however, the prevalence of cancers detected was substantially smaller (0.46%). Furthermore, several individuals underwent invasive procedures for ultimately benign conditions (three of four patients with nodules >10 mm who underwent biopsy had benign cytology; one had a thoracotomy that confirmed benign disease; three patients with mediastinal masses underwent biopsy and two had benign cysts). In two other studies, which used 5 mm CT slices, noncalcified nodules were detected in a much higher proportion of patients.  
In the Mayo Clinic study,  noncalcified nodules were detected in 51% of 1,520 patients at the prevalence screen and cumulatively in 74% after five subsequent annual screens.  Ninety-five percent of these nodules were less than 8 mm in diameter, for which the recommended follow-up was noncontrast CT in 3 to 6 months. However, eight patients had surgery for benign lesions, five of which appeared to grow on follow-up CT. In addition, screening with LDCT can detect abnormalities other than noncalcified nodules, including enlarged lymph nodes, abdominal aortic aneurysms, and renal and adrenal masses. During the first three rounds of screening in the Mayo Clinic study, 696 such abnormalities were found in the 1,520 patients.
In a 2008 systematic review of chest CT lung cancer screening studies, the mean proportion of patients with any incidental abnormality was 65.2% (95% confidence interval [CI], 63.5%–66.9%). The mean proportion of patients with clinically significant incidental findings—defined as any abnormality considered to require additional diagnostic workup—was 14.2% (95% CI, 13.2%–15.2%).  It is not clear whether the detection of these abnormalities produces a net benefit or a net harm. 
A less familiar harm is overdiagnosis,  the diagnosis of a condition that would not have become clinically significant had it not been detected by screening. In the case of screening with LDCT, overdiagnosis could lead to unnecessary diagnosis of lung cancer requiring some combination of surgery (e.g., lobectomy), chemotherapy, and radiation therapy. Although overdiagnosis is almost impossible to document in a living individual, autopsy studies suggest that many individuals die with lung cancer rather than from it. In one study, about one-sixth of all lung cancers found at autopsy had not been clinically recognized before death.  Even this may be an underestimate because autopsy probably fails to detect many small lung cancers that are detectable by CT.  Studies in Japan provide additional evidence that screening with LDCT could lead to a substantial amount of overdiagnosis.  In a study in which smokers and nonsmokers were annually screened for lung cancer between 1996 and 1998 using LDCT, the overall rate of screen-detected lung cancers was very similar in the two groups: 0.46% for smokers (mainly men) and 0.41% for nonsmokers (mainly women).  The nonsmoking group may have included individuals who were at an elevated risk for lung cancers for other reasons, but no information is provided on this point. A second study involving both smokers and nonsmokers reported a similar finding of a 1.1% lung cancer detection rate in both groups.  Confirmative studies are needed to establish the level of overdiagnosis that might be associated with CT screening for lung cancer. In that same population, the volume-doubling times of 61 lung cancers were estimated using an exponential model and successive CT images. Lesions were classified into three types: (1) type G (ground glass opacity), (2) type GS (focal glass opacity with a solid central component), and (3) type S (solid nodule). The mean-doubling times were 813 days, 457 days, and 149 days for types G, GS, and S, respectively. In this study, annual CT screening identified a large number of slowly growing adenocarcinomas that were not visible on chest x-ray. 
With completion of the NLST, there is now evidence that screening with LDCT can reduce lung cancer mortality risk in ever-smokers who have smoked 30 pack-years or more. The NLST included 33 centers across the United States. Eligible participants were between the ages of 55 years and 74 years at the time of randomization, had a history of at least 30 pack-years of cigarette smoking, and, if former smokers, had quit within the past 15 years. A total of 53,454 persons were enrolled; 26,722 persons were randomly assigned to screening with LDCT and 26,732 persons were randomly assigned to screening with chest x-ray. Any noncalcified nodule found on LDCT measuring at least 4 mm in any diameter and x-ray images with any noncalcified nodule or mass were classified as positive, although radiologists had the option of not calling a final screen positive if a noncalcified nodule had been stable on the three screening exams. The LDCT group had a substantially higher rate of positive screening tests than did the radiography group (round 1, 27.3% vs. 9.2%; round 2, 27.9% vs. 6.2%; and round 3, 16.8% vs. 5.0%). Overall, 39.1% of participants in the LDCT group and 16.0% in the radiography group had at least one positive screening result. Of those who screened positive, the false-positive rate was 96.4% in the LDCT group and 94.5% in the chest radiography group. This was consistent across all three rounds. 
In the LDCT group, 649 cancers were diagnosed after a positive screening test, 44 after a negative screening test, and 367 among participants who either missed the screening or received the diagnosis after the completion of the screening phase. In the radiography group, 279 cancers were diagnosed after a positive screening test, 137 after a negative screening test, and 525 among participants who either missed the screening or received the diagnosis after the completion of the screening phase. A total of 356 and 443 deaths from lung cancer occurred in the LDCT and chest x-ray groups, respectively, with a relative reduction in the rate of death from lung cancer of 20.0% (95% CI, 6.8–26.7) with LDCT screening. Overall mortality was reduced by 6.7% (95% CI, 1.2–13.6). The number needed to screen with low-dose CT to prevent one death from lung cancer was 320. 
Other randomized controlled trials of LDCT are under way in a number of countries.  Furthermore, NLST data are being analyzed to examine other important issues in lung cancer screening, including cost effectiveness, quality of life, and whether screening would benefit individuals younger than those enrolled in NLST and those with fewer than 30 pack-years of smoking exposure.
A Guide has been developed to help patients and physicians assess the benefits and harms of LDCT screening for lung cancer. 
The question of lung cancer screening dates back to the 1950s .Five studies of chest imaging, two of which were controlled, were undertaken during the 1950s and 1960s.         Two included sputum cytology as well.      The results of these studies suggested no overall benefit of screening, although design limitations prevented the studies from providing definitive evidence.
In the early 1970s, the National Cancer Institute funded the Cooperative Early Lung Cancer Detection Program,  which was designed to assess the ability of screening with radiologic chest imaging and sputum cytology to reduce lung cancer mortality in male smokers. The program comprised three separate randomized controlled trials, each enrolling about 10,000 male participants aged 45 years and older who smoked at least one pack of cigarettes a day in the previous year. One study was conducted at the Mayo Clinic,    one at Johns Hopkins University,    and one at Memorial Sloan-Kettering.     The Hopkins and Sloan-Kettering studies employed the same design: persons randomly assigned to the intervention arm received sputum cytology every 4 months and annual chest imaging, while persons randomly assigned to the control arm received annual chest imaging. Neither study observed a reduction in lung cancer mortality with screening.  The two studies were interpreted as showing no benefit of frequent sputum cytology when added to an annual regimen of chest x-ray.
The design of the Mayo Clinic study (known as the Mayo Lung Project, or MLP), was different. All potential participants were screened with chest imaging and sputum cytology, and those known or suspected to have lung cancer, as well as those in poor health, were excluded. Remaining persons were randomly assigned to either an intervention arm that received chest imaging and sputum cytology every 4 months for 6 years, or to a control arm that received a one-time recommendation at trial entry to receive the same tests on an annual basis. No reduction in lung cancer mortality was observed. The MLP was interpreted in the 1970s as showing no benefit of an intense screening regimen with chest x-ray and sputum cytology. The Czechoslovakian study began with a prevalence screen (chest imaging and sputum cytology) of 6,364 males aged 40 to 64 years who were current smokers with a lifetime consumption of at least 150,000 cigarettes.   All participants except the 18 diagnosed with lung cancer as a result of the prevalence screen were randomly assigned to one of two arms: an intervention arm, which received semi-annual screening for 3 years, or a control arm, which received screening during the third year only. The investigators reported 19 lung cancer deaths in the intervention arm and 13 in the control arm, and concluded that frequent screening was not necessary.
At the end of the 1980s, the relationship between screening with chest imaging (using traditional chest x-ray) and lung cancer mortality was not well understood. Although previous studies showed no benefit, they were not definitive, partly due to lack of statistical power. A multiphasic trial with ample statistical power, the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial,  began in 1992. PLCO enrolled 154,901 participants aged 55 to 74 years, including women (50%) and never smokers (45%). Half were randomly assigned to screening, and the other half were advised to receive their usual medical care. PLCO had 90% power to detect a 20% reduction in lung cancer mortality.
The lung component of PLCO addressed the question of whether annual single-view (posterior-anterior) chest x-ray was capable of reducing lung cancer mortality as compared with usual medical care. When the study began, all participants randomly assigned to screening were invited to receive a baseline and three annual chest x-ray screens, although the protocol ultimately was changed to screen never-smokers only three times. At 13 years of follow-up, 1,213 lung cancer deaths were observed in the intervention group, compared with 1,230 lung cancer deaths in the usual-care group (mortality relative risk, 0.99; 95% CI, 0.87–1.22). Sub-analyses suggested no differential effect by sex or smoking status.
Given the abundance and consistency of evidence, as well as the lack of benefit observed in the PLCO trial, it is appropriate to conclude that lung cancer screening with chest x-ray and/or sputum cytology, regardless of sex or smoking status, does not reduce lung cancer mortality.
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Description of the Evidence
Updated statistics with estimated new cases and deaths for 2015 (cited American Cancer Society as reference 1).
This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
If you have questions or comments about this summary, please send them to Cancer.gov through the Web site’s Contact Form. We can respond only to email messages written in English.
This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about lung cancer screening. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.
This summary is reviewed regularly and updated as necessary by the PDQ Screening and Prevention Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).
Board members review recently published articles each month to determine whether an article should:
Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.
Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's Contact Form. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.
Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Screening and Prevention Editorial Board uses a formal evidence ranking system in developing its level-of-evidence designations.
PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”
The preferred citation for this PDQ summary is:
National Cancer Institute: PDQ® Lung Cancer Screening. Bethesda, MD: National Cancer Institute. Date last modified <MM/DD/YYYY>. Available at: http://cancer.gov/cancertopics/pdq/screening/lung/HealthProfessional. Accessed <MM/DD/YYYY>.
Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in Visuals Online, a collection of over 2,000 scientific images.
The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the Coping with Cancer: Financial, Insurance, and Legal Information page.
More information about contacting us or receiving help with the Cancer.gov Web site can be found on our Contact Us for Help page. Questions can also be submitted to Cancer.gov through the Web site’s Contact Form.
For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.
The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
Write to us
For more information from the NCI, please write to this address:
Search the NCI Web site
The NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families. For a quick search, use the search box in the upper right corner of each Web page. The results for a wide range of search terms will include a list of "Best Bets," editorially chosen Web pages that are most closely related to the search term entered.
There are also many other places to get materials and information about cancer treatment and services. Hospitals in your area may have information about local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.
The NCI has booklets and other materials for patients, health professionals, and the public. These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials. Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities. NCI materials on these and other topics may be ordered online or printed directly from the NCI Publications Locator. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237).
Date last modified: 2015-02-13
The following organisations have financed parts of our PhD research project on improving the quality of online cancer information.
This site does not accept advertisemets.
|Back to the Cancer.gov
Questions? Mail them to us!